Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Biotechnology

Healthcare
$42.92 -1.86%

-$0.62 today

Market cap
$808.18M
Beta
1.18
P/E (TTM)
1.7
EPS (TTM)
$19.78
52W Low $18.14High $52.24

Volume 0.24M

Average 0.36M

RIGL EBITDA Margin

EBITDA as a percentage of revenue.

Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin narrows to 23.3%

EBITDA Margin was 23.3% in Q1 FY2026, down 2.9 pp from a year earlier. On a trailing-twelve-month basis it was 43.8%, up 19.9 pp year over year. Over 3 fiscal years it widened by 89.5 pp.

Context

  • EBITDA Margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 29.5% for the fiscal year ending Dec 2026, down from 44.7% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
23.3%-12.6 pp QoQ
Last fiscal yearDec 2025
44.7%+28.8 pp YoY
LTMMar 2026
43.8%+19.9 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.9 pp-54.4 pp-51.5 pp
1 year+28.8 pp-15.2 pp-44.0 pp
3 years+89.5 pp-7.6 pp-97.1 pp
5 years-16.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
44.7%
Year-over-year change
+28.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RIGL compares with its peers on the latest reported figures

  • RIGL's LTM Mar 2026 EBITDA Margin of 43.8% is the 2nd highest of the 8 companies compared; the peer median is -387.1%.
  • Its year-over-year change of +19.9 pp is the 3rd highest of 6, against a peer median of +6.3 pp.
  • Over three fiscal years its change of +89.5 pp compares with a peer median of +147.4 pp.
RIGL Competitors Peer median
EBITDA Margin for RIGL and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202646.0% +315.4 pp+147.4 pp
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202643.8% +19.9 pp+89.5 pp
EXELExelixis, Inc.LTM Jul 202643.0% +6.3 pp+23.9 pp
CCCCC4 Therapeutics, Inc.LTM Mar 2026-287.9% -44.6 pp+113.4 pp
VSTMVerastem, Inc.LTM Mar 2026-387.1% +1063.3 pp+2084.9 pp
ANLAdlai Nortye Ltd.LTM Jun 2024-979.5% ——
MREOMereo BioPharma Group plcLTM Mar 2026-7858.4% ——
CRDFCardiff Oncology, Inc.LTM Mar 2026-8329.5% -111.2 pp+2386.2 pp
CGEMCullinan Therapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
Peer median (excluding RIGL) -387.1%+6.3 pp+147.4 pp

Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue149.24M120.24M116.88M179.28M294.28M
Cost of Revenue1.08M1.75M7.11M18.65M19.62M
Gross Profit148.15M118.49M109.77M160.63M274.66M
Gross Margin99.3%98.5%93.9%89.6%93.3%
Research & Development65.24M60.27M24.52M23.38M33.3M
Selling, General & Admin91.89M112.45M105.74M113.06M115.9M
Operating Expenses160.65M174.04M130.26M136.44M149.2M
Depreciation & Amortization1.16M998K1.24M2.23M2.42M
EBITDA(11.29M)(53.87M)(16.98M)28.51M131.56M
EBITDA Margin-7.6%-44.8%-14.5%15.9%44.7%
Operating Income(12.5M)(55.55M)(20.49M)24.19M125.47M
Operating Margin-8.4%-46.2%-17.5%13.5%42.6%
Interest Income47K684K2.27M2.09M3.68M
Interest Expense4.86M3.71M6.87M7.92M7.32M
Other Income / Expenses(4.81M)(3.02M)(4.6M)(5.83M)(3.64M)
Income Before Tax(17.31M)(58.57M)(25.09M)18.37M121.83M
Pre-Tax Margin-11.6%-48.7%-21.5%10.2%41.4%
Income Tax Expense605K00881K(245.2M)
Net Income(17.91M)(58.57M)(25.09M)17.49M367.02M
Net Margin-12.0%-48.7%-21.5%9.8%124.7%
EPS (Basic)(1.10)(3.40)(1.44)0.9920.40
EPS (Diluted)(1.10)(3.40)(1.44)0.9919.48
Weighted Avg Shares17.05M17.24M17.4M17.58M17.99M
Weighted Avg Shares (Diluted)17.05M17.24M17.4M17.69M18.84M

Rigel Pharmaceuticals, Inc.

NASDAQ:RIGL

Intrinsic Alpha fair value

Locked

Current Price

$42.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.